Cosmos Health Inc. (NASDAQ: COSM) retired its $8.0 million senior secured convertible note issued to ATW one year ahead of its August 2027 maturity. The move eliminates further dilution from conversions and simplifies the company’s capital structure.

The healthcare group simultaneously withdrew its Form S-1 and Form S-3 registration statements, leaving no effective shelf registration or at-the-market offering program in place. This structural cleanup follows the expiration of 4,874,126 Series B warrants in May 2026 without exercise.

Balance Sheet Improvements

The retirement of the $8.0 million note, which carried a 9% coupon, significantly deleverages the balance sheet. In the second quarter, total liabilities fell by $6.27 million, or 13.3%, while stockholders’ equity rose 12.2%. The liabilities-to-assets ratio improved by 550 basis points.

Operational Efficiency

Operating cash requirements in the first half of 2026 were more than 30% below the average of the prior two years. This reduction reflects revenue growth, operating efficiencies, and improved operating leverage. Adjusted gross profit, adjusted gross margin, and adjusted EBITDA all improved in the second quarter.

Capital Structure & Liquidity

Cosmos Health maintains no structured warrants or variable interest rate instruments without a conversion price floor. Remaining warrants have fixed exercise prices with no reset provisions. The next tranche carries an exercise price of $0.95 per share, well above the current share price.

The company continues its $5.0 million share repurchase program. Its diversified asset base includes cash, digital assets, intellectual property, and real estate. Bitcoin holdings are currently in a gain position due to recent market strength.

What the Numbers Show

The simultaneous reduction in liabilities (13.3% drop) and increase in equity (12.2% rise) indicates a deliberate shift toward financial conservatism. By retiring high-cost debt (9% coupon) while maintaining a repurchase program, management is prioritizing capital efficiency over aggressive expansion, supported by a 30% cut in operating cash burn.

Cosmos Health Inc. (NASDAQ: COSM) projects its new nutraceutical, Oliv18, will generate over $6 million in incremental annual U.S. revenue within the next 12 to 18 months.

The Chicago-based healthcare group expects the product to deliver approximately $4.3 million in gross profit, reflecting an anticipated gross margin of roughly 72%.

Product Details and Market Strategy

Oliv18 is a whole olive polyphenol formulation certified as USDA and EU organic. It is produced through a 100% solvent-free process and targets the cardiovascular health and antioxidant categories in the United States.

The company plans a staged rollout, beginning with direct-to-consumer e-commerce before expanding into selected retail channels. The revenue forecast incorporates internal assumptions regarding pricing, sales volumes, repeat purchase behavior, and distribution growth.

Market Context

According to Grand View Research, the U.S. cardiovascular health supplements market was estimated at $2.11 billion in 2024 and is projected to reach $3.27 billion by 2030. Precedence Research valued the U.S. antioxidants market at $1.66 billion in 2025, with projections for it to nearly double to $3.18 billion by 2035.

Greg Siokas, CEO of Cosmos Health, stated that Oliv18 extends the company's "18 Series" into established consumer wellness categories where demand is shifting toward scientifically substantiated products.

What the Numbers Show

The projected gross margin of approximately 72% indicates that the company anticipates low variable costs relative to revenue for this specific product line. This high margin profile suggests that the incremental $6 million in revenue could contribute disproportionately to operating income compared to lower-margin segments of the business, assuming fixed costs remain stable during the rollout phase.